Pulse Biosciences Director Receives 30,000-Share Option Grant

Rhea-AI Filing Summary

Richard van den Broek, a director of Pulse Biosciences, was granted a stock option on 08/15/2025 to purchase 30,000 shares of common stock at an exercise price of $16.16 per share. The option becomes exercisable beginning 08/15/2025 and expires 08/15/2035. The shares subject to the option vest in equal monthly installments over one year, with the first installment on 09/15/2025, contingent on continued service.

Positive

• Option grant disclosed: Reporting Person received an option to purchase 30,000 shares.
• Clear vesting schedule: Shares vest in equal monthly installments over one year beginning 09/15/2025.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant: 30,000 options at $16.16, ten-year term, one-year monthly vesting.

The Form 4 documents a standard equity compensation event for a company director rather than a market-moving transaction. The option covers 30,000 underlying shares with a $16.16 exercise price and a 10-year contractual life, which is typical for incentive stock option arrangements. Vesting occurs monthly over one year starting September 15, 2025, and is conditioned on continued service. No exercise or sale occurred at filing.

Corporate Governance Expert

TL;DR: Governance disclosure confirms a director grant with service-based vesting and timely Form 4 filing.

The filing shows timely reporting by an officer acting as attorney-in-fact and discloses the grant details explicitly, including vesting schedule and exercise price. The one-year monthly vesting schedule ties ownership to continued service, which aligns with common governance practices for director incentives. The filing contains no indication of related-party transactions beyond the standard director grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider van den Broek Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van den Broek Richard

(Last) (First) (Middle)

601 BRICKELL KEY DRIVE

SUITE 1080

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.16	08/15/2025		A		30,000		(1)	08/15/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pulse Biosciences director Richard van den Broek receive on 08/15/2025 (PLSE)?

He was granted a stock option to buy 30,000 shares of common stock at an exercise price of $16.16 per share.

When do the options granted to the director vest and when do they expire?

The options vest in equal monthly installments over one year starting 09/15/2025 and expire on 08/15/2035.

Is the reported transaction an acquisition or a disposition on Form 4 for PLSE?

It is an acquisition (A) of a derivative security (a stock option) reported on 08/15/2025.

What is the exercise price of the stock option reported for PLSE?

The exercise (conversion) price is $16.16 per share.

Who signed the Form 4 filing for this transaction?

The Form 4 was signed by Kenneth B. Stratton, as Attorney-in-Fact on behalf of the reporting person on 08/19/2025.